High Neutrophil-to-Lymphocyte Ratio and Patients With Hemodialysis
ConditionHemodialysis Patient
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorSohag University
About this trial
To explore the role of neutrophil-to-lymphocyte ratio ( NLR ) and platelet-to-lymphocyte ratio ( PLR ) in predicting mortality in hemodialysis (HD) patients.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
All cases with age ≥ 18 years from both sexes female and male, having end-stage renal disease (ESRD), who have been on hemodialysis for at least three months and divided to 4 groups according to the median of NLR and PLR
Disqualifiers
• Patients aged < 18 years old.
Patient with autoimmune disease.
Patient with liver cirrhosis.
Patients with immunodeficiency.
Trial population
patients on regular hemodialysis
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
neutrophil lymphocyte ratio and platelet lymphocyte ratio
Other interventionexplore the role of neutrophil-to-lymphocyte ratio ( NLR ) and platelet-to-lymphocyte ratio ( PLR ) in predicting mortality in hemodialysis (HD) patients
Treatment groups
No treatment groups listed
Trial outcomes
Primary outcomes
1
Mortality
The primary outcome measures in the study "High Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio Are Associated with Poor Survival in Patients with Hemodialysis" is :- All-cause mortality, encompassing death from any cause These is the endpoint used to evaluate the prognostic significance of NLR and PLR in hemodialysis patients.
Time frame
6 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: